Construction of a Recombinant B-Cell Epitope Vaccine Based on a
 Der P1
 -Derived Hypoallergen:a Bioinformatics Approach

Fanuel, Songwe; Tabesh, Saeideh; Mokhtarian, Kobra; Saroddiny, Esmaeil; Fazlollahi, Mohammad Reza; Pourpak, Zahra; Falak, Reza; Kardar, Gholam Ali

doi:10.2217/imt-2017-0163

Cited by 16 publications

(12 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The supernatant was collected by centrifugation for 30 min at 15,000 rpm and the urea was removed by stepwise dialysis. Then the dialyzate was centrifuged for 30 min at 12,000 rpm [28]. B5M was eluted with a 50-300 mM imidazole gradient in native wash buffer and concentrated using an ultrafiltration centrifuge tube with a molecular weight cut of 30 kDa.…”

Section: Expression and Purification Of B5mmentioning

confidence: 99%

Alteration of Allergen Fold of Bos d 5 into a Hypoallergenic Vaccine for Immunotherapy of Cow’s Milk Allergy

Cui

Lin

et al. 2021

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Cow’s milk allergy (CMA) is the most common IgE-mediated food allergy and Bos d 5 is the major allergen in cow’s milk proteins. More than 60% of the patients with CMA are sensitized to this protein. Methods and Results: A recombinant protein, encoded by a synthetic gene and consisting of reassembled Bos d 5 fragments, was expressed in E. coli strain BL21 (DE3) cells and purified to homogeneity. The B5M lacked relevant IgE-reactivity and allergenic activity compared with Bos d 5 in dot-blot and basophil activation assays. T-cell proliferation experiments demonstrated that B5M preserved the main T cell epitopes of Bos d 5. Immunization of rabbits with B5M induced protective IgG antibodies that blocked the binding of patients’ IgE antibodies to the wild-type allergen and inhibited the degranulation of basophils induced by Bos d 5. Conclusion: Thus, we developed a new strategy, which was based on rational molecular reassembly for allergen-specific immunotherapy (AIT) of CMA and food allergy.

show abstract

Section: Expression and Purification Of B5mmentioning

confidence: 99%

Alteration of Allergen Fold of Bos d 5 into a Hypoallergenic Vaccine for Immunotherapy of Cow’s Milk Allergy

Cui

Lin

et al. 2021

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…It was also more effective in reducing IL-4 (Figure 4A) AND IL-13 (Figure 4B) cytokines than HDM extract, which was in line with the Fanuel et al study. 22 On the other hand, a decrease in the level of cytokines IL-4 and IL-13 in BALF was observed in similar studies using DerP2 peptides by Wang, as well as studies by Xiao-Dong et al separately. They have also introduced this peptide as a candidate for allergy vaccines.…”

Section: Discussionmentioning

confidence: 58%

“…The recombinant fusion vaccine was developed by our previous group. 22 The final sequence of the vaccine is DpTTDp. To construct the recombinant fusion vaccine, two predicted hypoallergenic peptides were fused together with a partial fragment C of the TT sequence, which is composed of 155 amino acids.…”

Section: Construction Of the Recombinant Fusion Vaccinementioning

confidence: 99%

Allergen‐specific immunotherapy by recombinant Der P1 allergen‐derived peptide‐based vaccine in an allergic mouse model

Moghanloo

Forouzanfar

Jafarinia

et al. 2023

Immunity Inflam & Disease

Self Cite

View full text Add to dashboard Cite

Aim: Increased IgE levels have made house dust mite allergens one of the most frequent causes of allergies worldwide. Treatment reduces the IgE antibodies and types two cytokines, namely interleukin-4 (IL-4) and IL-13.Although existing treatments significantly reduce IgE or IL-4/IL-13, they are very costly. This study aimed to construct a recombinant protein derived from rDer p1 peptides in the form of an immunotherapy approach and to measure the response of IgE and IgG antibodies.Methods: The proteins were isolated, purified, and evaluated using the SDS-PAGE and Bradford test and confirmed by using Western blot. To evaluate immunotherapy efficiency, 24 BALB/C mice were sensitized intraperitoneally with house dust mites (HDM) adsorbed to Aluminum hydroxide (Alum) and randomly divided into four groups of six: control sensitized, HDM extract, rDer p1, and DpTTDp vaccine. To immunization, four groups of random mice were each treated with phosphate-buffered saline, 100 μg of rDer p1 protein, DpTTDp, or HDM extract, every 3 days. Direct ELISA determined HDMspecific IgG and IgE subclasses. Data were analyzed in SPSS and Graph pad prism software. Values of p < .05 were considered significant.Results: After immunization of mice, the rDer P1 and recombinant vaccine like HDM extract increased IgG antibody titer and decreased IgE-dependent reactivity in allergic mice to rDer P1. Also, the levels of inflammatory IL-4 and IL-13 cytokines as allergic stimulants decreased. Conclusion:The use of present available recombinant proteins is considered a viable, cost-effective, and long-term option for providing effective HDM allergy immunotherapy vaccines without side effects.

show abstract

“…After getting the protein DpTTDp, mice were immunized to assess the allergenic potential and production of IgG antibodies. It was observed in this study that the protein DpTTDp induced relevant levels of IgG antibodies, which act by inhibiting the interaction with IgE of patients allergic to mites, making it a candidate for a vaccine based on B cell epitope for the treatment of allergies to mites [32].…”

Section: Carrier-bound B-cell Epitope-containing Peptidesmentioning

confidence: 85%

Current Developments in Allergen-Specific Immunotherapy: A Brief Review

Bartholazzi¹,

Lodi²,

Machado³

2023

Allergic Disease - New Developments in Diagnosis and Therapy

View full text Add to dashboard Cite

Immunotherapy is a treatment for patients with type I-mediated allergic diseases. Molecular forms of allergen-specific immunotherapy (AIT), based on inducing immunological tolerance characterized by increased IL-10, TGF-β, and IgG4 levels, and Treg cell are continuously emerging to improve the efficacy of the treatment, shorten the duration of protocols, and prevent any side effects. This review covers the recent progress in AIT and routes of antigen administration. Classical immunotherapy uses allergen extracts obtained from natural sources. Limitations of the uses of these extracts, such as sensitizations with nonspecific agents, can be avoided using purified components, hypoallergenic recombinant proteins, and vaccines based on peptides (epitopes). However, these molecules have low immunogenicity requiring new carriers or more effective adjuvants. Vaccines based on carrier-bound B-cell epitope-containing peptides and the constructions of allergens coupled to virus-like particles (VLPs) are under evaluation. The possibility of vaccinating with DNA encoding the allergen to obtain an allergen-specific Th1 and IgG response is in development and the success of messenger ribonucleic acid (mRNA) vaccines against severe acute respiratory syndrome Coronavirus 2 must encourage as well the re-exploration of mRNA vaccine platform for innovative AIT.

show abstract

Construction of a Recombinant B-Cell Epitope Vaccine Based on a Der P1 -Derived Hypoallergen:a Bioinformatics Approach

Abstract: The protein represents a promising HDM-allergy immunotherapy candidate vaccine.

Cited by 16 publications

References 46 publications

Alteration of Allergen Fold of Bos d 5 into a Hypoallergenic Vaccine for Immunotherapy of Cow’s Milk Allergy

Alteration of Allergen Fold of Bos d 5 into a Hypoallergenic Vaccine for Immunotherapy of Cow’s Milk Allergy

Allergen‐specific immunotherapy by recombinant Der P1 allergen‐derived peptide‐based vaccine in an allergic mouse model

Current Developments in Allergen-Specific Immunotherapy: A Brief Review

Contact Info

Product

Resources

About